Skip to content

Common Stock at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$292M0.0%
Amgen logo
AmgenAMGN
2.8B0.0%
Vera Therapeutics logo
Vera TherapeuticsVERA
$72K+12.5%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$1K
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$6K0.0%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$5K+66.7%

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s common stock?
Climb Bio, Inc. (CLYM) reported common stock of $5K in Q1 2026.
How has Climb Bio, Inc.'s common stock changed year-over-year?
Climb Bio, Inc.'s common stock decreased by 28.6% year-over-year, from $7K to $5K.
What is the long-term trend for Climb Bio, Inc.'s common stock?
Over 5 years (2020 to 2025), Climb Bio, Inc.'s common stock has grown at a 38.0% compound annual growth rate (CAGR), from $1K to $5K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).